Activated CIK + CD3-MUC1 bispecific antibody

This investigational cell-based immunotherapy is being developed by Fuda Cancer Hospital in Guangzhou, China, for the treatment of MUC1-positive advanced breast cancer. The therapy utilizes cytokine-induced killer (CIK) cells—a heterogeneous population of immune effector cells dominated by CD3+CD56+ natural killer-like T lymphocytes—that are "armed" with a bispecific antibody. This bispecific antibody simultaneously targets the CD3 receptor on T cells and the Mucin 1 (MUC1) antigen, a tumor-associated glycoprotein that is frequently overexpressed and abnormally glycosylated in epithelial malignancies. By bridging the effector CIK cells to MUC1-expressing tumor cells, the therapy facilitates targeted cytotoxic activity. In clinical investigation, the CIK cells are further activated using a PD-1 inhibitor to enhance their anti-tumor efficacy. This approach is currently being evaluated in Phase II clinical trials in combination with cryotherapy.

Other names

Activated CIK armed with anti-CD3-MUC1 bispecific antibodyTarget Activated CIKanti-CD3-MUC1 bispecific antibody-armed CIK cellsanti-CD-3-MUC1 bispecific antibody-armed CIK cellsanti-CD 3-MUC1 bispecific antibody-armed CIK cells